Summary of Price Reductions for Drugs Subject to Price Disclosure pre-1 December 2010

First Round of PBS Price Disclosure – 1 December 2009
Drug MOA Weight average percentage reduction
Doxorubicin Injection / intravesical 63.54%
Mitozantrone Injection 34.42%
Ondansetron Injection 15.37%

 

Second Round of PBS Price Disclosure – 1 April 2010
Drug MOA Weight average percentage reduction
Fluconazole Oral 55.26%
Vancomycin Injection 71.80%

 

Third Round of PBS Price Disclosure – 1 April 2010
Drug MOA Weight average percentage reduction
Carvedilol Oral 27.29%

 

Fourth Round of PBS Price Disclosure – 1 August 2010
Drug MOA Weight average percentage reduction
Cefalotin Injection 41.13%
Doxorubicin Injection / intravesical 34.62%
Meloxicam Oral 17.99%
Mitozantrone Injection 13.33%
Ondansetron Injection 17.61%

 

Fifth Round of PBS Price Disclosure – 1 April 2011
Drug MOA Weight average percentage reduction
Alendronic Acid Oral 22.96%
Cisplatin Injection 39.02%
Fluconazole Injection 27.52%
Fluconazole Oral 38.48%
Risperidone Oral 17.37%
Vancomycin Injection 12.48%

 

Sixth Round of PBS Price Disclosure – 1 April 2011
Drug MOA Weight average percentage reduction
Carvedilol Oral 11.90%
Gemcitabine Injection 37.00%
Irinotecan Injection 61.40%
Paclitaxel Injection 52.58%

 

Seventh Round of PBS Price Disclosure – 1 August 2011
Drug MOA Weight average percentage reduction
Bicalutamide Oral 10.31%
Escitalopram Oral 33.80%
Meloxicam Oral 12.40%
Mitozantrone Injection 10.61%
Ondansetron Oral 39.44%
Ondansetron Injection 22.51%
Oxaliplatin Injection 72.54%
Sodium Chloride Injection 43.54%
Sodium Lactate Compound Injection 45.61%
Valproic Acid Oral 10.83%
Last updated
1 December 2010